Global Soft Tissue Sarcoma Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

08/feb/2018 10:18:52 precision business insights Contatta l'autore

Questo comunicato è stato pubblicato più di 6 mesi fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Soft tissue sarcoma treatment market: Soft tissue sarcoma is the rare and diverse group of cancers that develop from soft tissues such as blood vessels, muscles, fats, nerves, and deep skin tissues etc. There are around 50 different types of soft tissue sarcoma have been identified, the common types of soft tissue sarcoma are liposarcomas which develop from fat cells, and leiomyosarcomas, which arise from smooth muscle tissue. The soft tissue sarcoma can be treated by the combined chemotherapy, radiotherapy, and surgery to remove the tumour. If surgical procedure is not required, chemotherapy alone can be used.

 Global Market Outline: Soft Tissue Sarcoma Treatment Market 

 Increase in the prevalence and incidence of different types of cancers, rise in the number of soft tissue sarcoma cases, increase in the R&D activities on drugs and other biological therapies, patent expiry of branded drugs, increase in the healthcare expenditure and rise in quality patient care are expected to fuel the soft tissue sarcoma treatment market over the forecast period. However, high cost for the radiotherapy and chemotherapy, stringent regulatory guidelines, and adverse effects associated with the treatment might hinder the growth of soft tissue sarcoma treatment market over the forecast timeframe.

 

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-soft-tissue-sarcoma-treatment-market/#ulp-4H8Z4LpNMLEuOnnx

 

 

The soft tissue sarcoma treatment market has been segmented on basis of disease type, treatment type, and end user

 

Based on the treatment type, soft tissue sarcoma treatment market is segmented into following:

·         Targeted Therapy

·         Chemotherapy

·         Anti-angiogenesis drugs

·         Radiation Therapy

o    Internal Radiation Therapy

o    External Radiation Therapy

 

Based on the disease type, soft tissue sarcoma treatment market is segmented into following:

·         Local Sarcoma

·         Regional Sarcoma

·         Metastatic Sarcoma

 

Based on the distribution channel, soft tissue sarcoma treatment market is segmented into following:

·         Hospitals

·         Oncology Clinics

·         Long Term Care Centres

 

To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-soft-tissue-sarcoma-treatment-market/#ulp-c654SbFYO64MsOhu

 

 

Soft tissue sarcoma treatment market is in growing stage as very fewer products in the market are currently approved to treat various types of soft tissue sarcoma. Various international companies are very active in the soft tissue sarcoma treatment market in terms of product launches, research, and development activities. For instance, in 2012, Threshold Pharmaceuticals Inc. signed a global license and co-development agreement for Evofosfamide, which is the most advanced first-line drug for soft tissue sarcoma with Merck KGaA. Merck KGaA paid US$ 110 Mn as upfront payment and milestone payments to Threshold, and additionally, Merck KGaA covers 70% of all evofosfamide development expenses. GSK’s Votrient (pazopanib) is approved for second-line treatment, and another drug Aldoxorubicin is approved as first-line drug for the treatment of soft tissue sarcoma. Currently, doxorubicin is commonly used for the treatment of soft tissue sarcoma.

 

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/global-soft-tissue-sarcoma-treatment-market/#ulp-14mlyhjMGhVjZqa3

 

 

Geographically, soft tissue sarcoma treatment market segmented into following regions Viz. North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America may lead the soft tissue sarcoma treatment market owing to increase in the prevalence of the disease. According to American Cancer Society, approximately 12,390 people in 2016 are suffering soft tissue sarcoma and cancer. Europe holds a key share in soft tissue sarcoma treatment market attributed to change in lifestyle, increase in R&D activities for the development of new drugs. Asia-Pacific region accounts for a significant growth due to increase in cancer cases, and rise in awareness about advanced soft tissue sarcoma treatment.

 

Some of the players in the soft tissue sarcoma treatment market are GlaxoSmithKline plc (U.K.), Eli Lilly and Company (U.S.), Pfizer, Inc. (U.S.), Bristol-Myers Squibb (U.S.), F. Hoffmann-La Roche AG (Genentech) (Switzerland), Johnson & Johnson Services, Inc. (U.S.), Teva Pharmaceutical Industries Ltd (Israel), and Celgene Corporation (U.S.) to name a few.

 

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/global-soft-tissue-sarcoma-treatment-market/
blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl